Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Mer­ck ex­ecs are mak­ing a triple play in a sud­den leap in­to the R&D cam­paign against Covid-19. And they have more BAR­DA cash back­ing them up on the move.

Tues­day morn­ing the phar­ma gi­ant si­mul­ta­ne­ous­ly an­nounced plans to buy an Aus­tri­an biotech that has been work­ing on a pre­clin­i­cal vac­cine can­di­date, added a col­lab­o­ra­tion on an­oth­er vac­cine with the non­prof­it IAVI and inked a deal with Ridge­back Bio­ther­a­peu­tics on an ear­ly-stage an­tivi­ral.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER